Clinical Trial Detail

NCT ID NCT02561234
Title A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Aeglea Biotherapeutics
Indications

Advanced Solid Tumor

lung small cell carcinoma

melanoma

uveal melanoma

Therapies

Pegzilarginase

Age Groups: senior adult

No variant requirements are available.